; (4) an analysis of what is known about positive and negative impacts that prescribing limitations, both State and Federal, have on patient medical outcomes, including for chronic pain patients; and (5) an analysis of what is known about the costs to payers of using abuse-deterrent formulations of opioid pain medications, compared to opioid pain medications without abuse-deterrent features. 5. Study on feasibility of replacing statutory limits with clinical guidelines on opioid prescribing The Commissioner of Food and Drugs shall— (1) conduct a study on the feasibility of— (A) replacing the prescribing limits in section 303(k)(1) of the Controlled Substances Act, as added by section 2 of this Act, with evidence-based clinical guidelines to inform opioid selection, dosage, duration, follow up, and discontinuation, including guidelines on the first opioid prescription for patients for an acute pain diagnosis to ensure that no greater quantity than needed is prescribed for the expected duration of pain severe enough to require opioids; and (B) the incorporation into routine medical visits of evidence-based screening tools for the misuse of opioids and other controlled substances; and (2) not later than the date that is 2 years after the date of enactment of this Act, submit to the Congress, and post on the public website of the Food and Drug Administration, a report on the results of such study.